These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 32112512)

  • 21. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America.
    Ravasi G; Grinsztejn B; Baruch R; Guanira JV; Luque R; Cáceres CF; Ghidinelli M
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21113. PubMed ID: 27760687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.
    Cremin I; McKinnon L; Kimani J; Cherutich P; Gakii G; Muriuki F; Kripke K; Hecht R; Kiragu M; Smith J; Hinsley W; Gelmon L; Hallett TB
    Lancet HIV; 2017 May; 4(5):e214-e222. PubMed ID: 28233660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya.
    Roberts DA; Barnabas RV; Abuna F; Lagat H; Kinuthia J; Pintye J; Bochner AF; Forsythe S; Gomez GB; Baeten JM; John-Stewart G; Levin C
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25296. PubMed ID: 31328443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
    Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
    BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study.
    Were D; Musau A; Mutegi J; Ongwen P; Manguro G; Kamau M; Marwa T; Gwaro H; Mukui I; Plotkin M; Reed J
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25537. PubMed ID: 32602658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
    Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
    AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis.
    Stelzle D; Godfrey-Faussett P; Jia C; Amiesimaka O; Mahy M; Castor D; Hodges-Mameletzis I; Chitembo L; Baggaley R; Dalal S
    PLoS Med; 2021 Jan; 18(1):e1003482. PubMed ID: 33428611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.
    Hankins C; Macklin R; Warren M
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19973. PubMed ID: 26198343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.
    Koechlin FM; Fonner VA; Dalglish SL; O'Reilly KR; Baggaley R; Grant RM; Rodolph M; Hodges-Mameletzis I; Kennedy CE
    AIDS Behav; 2017 May; 21(5):1325-1335. PubMed ID: 27900502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention.
    Morton JF; Celum C; Njoroge J; Nakyanzi A; Wakhungu I; Tindimwebwa E; Ongachi S; Sedah E; Okwero E; Ngure K; Odoyo J; Bulya N; Haberer JE; Baeten JM; Heffron R;
    J Acquir Immune Defic Syndr; 2017 Jan; 74 Suppl 1(Suppl 1):S15-S22. PubMed ID: 27930607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
    Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
    J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.